EXPIRES at 11:59pm: Full Transcript of Our Urgent Broadcast on India's Revival
Here is the latest financial fact sheet of Dishman Pharma. For more details, see the Dishman Pharma quarterly results and Dishman Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 2.9 |
No. of shares | m | 161.39 |
% ch week | % | 3.5 |
% ch 1-mth | % | -2.4 |
% ch 12-mth | % | 96.4 |
52 week H/L | Rs | 346.3/127.6 |
No. of Mths Year Ending |
12 Mar-12* |
12 Mar-13* |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
5-Yr Chart Click to enlarge
|
---|
DISHMAN PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 107 | 122 | 107 | 183 | 374 | |
Low | Rs | 35 | 42 | 39 | 83 | 129 | |
Sales per share (Unadj.) | Rs | 139.3 | 157.7 | 171.7 | 196.9 | 197.8 | |
Earnings per share (Unadj.) | Rs | 7.0 | 12.4 | 13.5 | 14.8 | 21.2 | |
Diluted earnings per share | Rs | 3.5 | 6.2 | 6.8 | 7.4 | 10.6 | |
Cash flow per share (Unadj.) | Rs | 16.5 | 22.8 | 27.0 | 33.5 | 34.7 | |
Dividends per share (Unadj.) | Rs | 1.20 | 1.20 | 1.20 | 2.00 | 2.00 | |
Adj. dividends per share | Rs | 0.60 | 0.60 | 0.60 | 1.00 | 1.00 | |
Dividend yield (eoy) | % | 1.7 | 1.5 | 1.6 | 1.5 | 0.8 | |
Book value per share (Unadj.) | Rs | 115.3 | 128.2 | 146.4 | 153.4 | 179.9 | |
Adj. book value per share | Rs | 57.7 | 64.1 | 73.2 | 76.7 | 89.9 | |
Shares outstanding (eoy) | m | 80.69 | 80.69 | 80.69 | 80.69 | 80.69 | |
Bonus/Rights/Conversions | - | - | - | - | - | ||
Price / Sales ratio | x | 0.5 | 0.5 | 0.4 | 0.7 | 1.3 | |
Avg P/E ratio | x | 10.1 | 6.6 | 5.4 | 8.9 | 11.9 | |
P/CF ratio (eoy) | x | 4.3 | 3.6 | 2.7 | 4.0 | 7.2 | |
Price / Book Value ratio | x | 0.6 | 0.6 | 0.5 | 0.9 | 1.4 | |
Dividend payout | % | 17.1 | 9.7 | 8.9 | 13.5 | 9.4 | |
Avg Mkt Cap | Rs m | 5,729 | 6,617 | 5,902 | 10,691 | 20,306 | |
No. of employees | `000 | 1.0 | 1.1 | 0.9 | 0.9 | 0.8 | |
Total wages/salary | Rs m | 2,941 | 3,509 | 4,123 | 4,232 | 5,355 | |
Avg. sales/employee | Rs Th | 11,541.3 | 12,059.0 | 14,848.0 | 18,430.9 | 19,252.7 | |
Avg. wages/employee | Rs Th | 3,019.6 | 3,326.2 | 4,419.4 | 4,909.6 | 6,459.5 | |
Avg. net profit/employee | Rs Th | 582.8 | 950.6 | 1,171.2 | 1,389.9 | 2,064.1 |
DISHMAN PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 11,241 | 12,722 | 13,853 | 15,887 | 15,961 | |
Other income | Rs m | 129 | 178 | 249 | 869 | 265 | |
Total revenues | Rs m | 11,370 | 12,900 | 14,102 | 16,757 | 16,226 | |
Gross profit | Rs m | 2,245 | 2,901 | 3,321 | 3,128 | 4,103 | |
Depreciation | Rs m | 765 | 838 | 1,086 | 1,507 | 1,091 | |
Interest | Rs m | 729 | 788 | 921 | 897 | 944 | |
Profit before tax | Rs m | 879 | 1,453 | 1,564 | 1,593 | 2,334 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 1 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 312 | 450 | 471 | 394 | 624 | |
Profit after tax | Rs m | 568 | 1,003 | 1,093 | 1,198 | 1,711 | |
Gross profit margin | % | 20.0 | 22.8 | 24.0 | 19.7 | 25.7 | |
Effective tax rate | % | 35.4 | 31.0 | 30.1 | 24.8 | 26.7 | |
Net profit margin | % | 5.0 | 7.9 | 7.9 | 7.5 | 10.7 |
DISHMAN PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 6,239 | 6,733 | 8,245 | 10,135 | 11,018 | |
Current liabilities | Rs m | 6,547 | 7,127 | 9,028 | 11,048 | 9,517 | |
Net working cap to sales | % | -2.7 | -3.1 | -5.7 | -5.7 | 9.4 | |
Current ratio | x | 1.0 | 0.9 | 0.9 | 0.9 | 1.2 | |
Inventory Days | Days | 87 | 97 | 112 | 103 | 110 | |
Debtors Days | Days | 61 | 21 | 38 | 50 | 35 | |
Net fixed assets | Rs m | 14,391 | 14,579 | 15,717 | 15,827 | 16,304 | |
Share capital | Rs m | 161 | 161 | 161 | 161 | 161 | |
"Free" reserves | Rs m | 8,225 | 9,051 | 10,031 | 11,167 | 12,907 | |
Net worth | Rs m | 9,307 | 10,345 | 11,813 | 12,378 | 14,516 | |
Long term debt | Rs m | 5,121 | 4,336 | 4,121 | 3,302 | 4,189 | |
Total assets | Rs m | 22,490 | 22,911 | 26,277 | 28,089 | 29,805 | |
Interest coverage | x | 2.2 | 2.8 | 2.7 | 2.8 | 3.5 | |
Debt to equity ratio | x | 0.6 | 0.4 | 0.3 | 0.3 | 0.3 | |
Sales to assets ratio | x | 0.5 | 0.6 | 0.5 | 0.6 | 0.5 | |
Return on assets | % | 5.8 | 7.8 | 7.7 | 7.5 | 8.9 | |
Return on equity | % | 6.1 | 9.7 | 9.3 | 9.7 | 11.8 | |
Return on capital | % | 11.1 | 15.3 | 15.6 | 15.9 | 17.5 | |
Exports to sales | % | 30.3 | 28.3 | 27.8 | 22.6 | 24.8 | |
Imports to sales | % | 7.2 | 4.7 | 6.3 | 5.6 | 3.7 | |
Exports (fob) | Rs m | 3,404 | 3,595 | 3,855 | 3,598 | 3,956 | |
Imports (cif) | Rs m | 806 | 599 | 869 | 891 | 596 | |
Fx inflow | Rs m | 3,974 | 4,210 | 3,966 | 4,576 | 4,952 | |
Fx outflow | Rs m | 905 | 695 | 954 | 974 | 697 | |
Net fx | Rs m | 3,069 | 3,515 | 3,011 | 3,601 | 4,255 |
DISHMAN PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 1,536 | 1,651 | 3,445 | 2,937 | 2,786 | |
From Investments | Rs m | -1,040 | -1,173 | -2,568 | -1,581 | -1,529 | |
From Financial Activity | Rs m | -680 | -502 | -741 | -1,420 | -941 | |
Net Cashflow | Rs m | -185 | -23 | 136 | -64 | 316 |
Share Holding
|
Company Information
|
CHM: Janmejay R. Vyas (MD) | COMP SEC: Tushar D. Shah | YEAR OF INC: 1983 | BSE CODE: 532526 | FV (Rs): 2 | DIV YIELD (%): 0.3 |
More Pharmaceuticals Company Fact Sheets: PFIZER NEULAND LABS FDC PROCTER & GAMBLE HEALTH J.B.CHEMICALS
Compare DISHMAN PHARMA With: PFIZER NEULAND LABS FDC PROCTER & GAMBLE HEALTH J.B.CHEMICALS
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets ended on a flat note on Friday. Benchmark indices gave up early gains during closing hours on Friday as investors worried about the surge in Covid cases in the country
Ajit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More